Home Angiotensin-converting enzyme (ACE) I/D corrected serum ACE activity and severity assessment of community-acquired pneumonia
Article
Licensed
Unlicensed Requires Authentication

Angiotensin-converting enzyme (ACE) I/D corrected serum ACE activity and severity assessment of community-acquired pneumonia

  • Ewoudt M.W. van de Garde , Henrik Endeman , Vera H.M. Deneer , Douwe H. Biesma , Henk J.T. Ruven , Heleen van Velzen-Blad , Hubert G.M. Leufkens and Jules M.M. van den Bosch
Published/Copyright: October 10, 2007
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 45 Issue 10

Abstract

Background: Various studies have described decreased serum angiotensin-converting enzyme (ACE) activity in patients with pneumonia. The aim of the present study was to evaluate the role of ACE in pneumonia by comparing ACE insertion/deletion (I/D) genotype corrected serum ACE activity and to establish whether the severity of the disease correlates with lower ACE activity.

Methods: This was a prospective hospital-based observational study including 134 patients with pneumonia. Serum ACE activity was determined at admission, on days 2, 3, 5 and 10 of hospital stay, and at recovery. Based on ACE genotype and reference values, corresponding Z-scores were calculated. Disease severity, quantified by the acute physiology score (APS), and clinical outcome were compared between tertile groups of the Z-scores.

Results: A significant decrease in serum ACE activity during an episode of pneumonia with return to control range during recovery was observed for all three genotypes (II, ID and DD). The calculated Z-scores showed a negative correlation with APS scores (p=0.050). No significant association between decreased serum ACE activity and clinical outcome was observed.

Conclusions: Serum ACE activity is significantly decreased during the acute phase of pneumonia. Despite correction for ACE I/D genotype, decreased ACE activity did not show a prognostic value. Further studies are needed to examine the mechanisms behind and diagnostic value of decreased ACE activity in community-acquired pneumonia.

Clin Chem Lab Med 2007;45:1326–31.


Corresponding author: Ewoudt M.W. van de Garde, Department of Clinical Pharmacy, St. Antonius Hospital, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands Phone: +31-30-6092612, Fax: +31-30-6093080,

Received: 2007-3-26
Accepted: 2007-5-21
Published Online: 2007-10-10
Published in Print: 2007-10-01

©2007 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Atrial natriuretic peptide and related peptides
  2. The −374A allele of the receptor for advanced glycation end products (RAGE) gene promoter is a protective factor against cardiovascular lesions in type 2 diabetes mellitus patients
  3. Biochemical properties of endogenous presenilin 1 and presenilin 2 in cultured human B-lymphocytes
  4. CD36 polymorphism and its relationship with body mass index and coronary artery disease in a Korean population
  5. Preservation of RNA for functional analysis of separated alleles in yeast: comparison of snap-frozen and RNALater® solid tissue storage methods
  6. Mother-child double incompatibility at vWA and D5S818 loci in paternity testing
  7. Matrix metalloprotease-2 and -9 concentration and activity in serum and culture medium samples: a methodological reappraisal
  8. Are changes in blood-ethanol concentration during storage analytically significant? Importance of method imprecision
  9. Measurement of arginine derivatives in pediatric patients with chronic kidney disease using high-performance liquid chromatography-tandem mass spectrometry
  10. The soluble transferrin receptor reflects tumor load in chronic lymphocytic leukemia
  11. Calculated low-density lipoprotein cholesterol remains a viable and important test for screening and targeting therapy
  12. Angiotensin-converting enzyme (ACE) I/D corrected serum ACE activity and severity assessment of community-acquired pneumonia
  13. Differentiating transudative from exudative pleural effusion: should we measure effusion cholesterol dehydrogenase?
  14. Association of classical and related inflammatory markers with high-sensitivity C-reactive protein in healthy individuals: results from the Stanislas cohort
  15. Cytokines and growth factors in mostly atherosclerotic patients on hemodialysis determined by biochip array technology
  16. Use of a solid-phase extraction with radioimmunoassay to identify the proportional bias of clinical B-type natriuretic peptide immunoassay: the impact of plasma matrix and antibody multispecificity
  17. High plasma levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and interleukin-8 (IL-8) characterize patients prone to ventricular fibrillation complicating myocardial infarction
  18. Methylprednisolone, cortisol and the cell-mediated immune response in children after ventricular septal defect repair
  19. Standardization of γ-glutamyltransferase assays by intermethod calibration. Effect on determining common reference limits
  20. The effect of endurance exercise-induced lactacidosis on biochemical markers of bone turnover
  21. Serum biobank certification and the establishment of quality controls for biological fluids: examples of serum biomarker stability after temperature variation
  22. Diagnostic usefulness of a third-generation anti-cyclic citrulline antibody test in patients with recent-onset polyarthritis
  23. Clinical significance of the laboratory determination of low serum copper in adults
  24. National survey on critical values reporting in a cohort of Italian laboratories
  25. Influence of haemodialysis on the NT-proBNP plasma concentration
  26. C–588T polymorphism of the human glutamate-cysteine ligase modifier subunit gene is not associated with the risk and extent of ischemic heart disease in a German cohort
  27. Has homocysteine shrunk?
Downloaded on 16.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2007.268/html
Scroll to top button